Tapentadol ER Shown to Be Effective for Chronic Diabetic Peripheral Neuropathy
A study presented at PAINWeek 2012 reported that tapentadol extended-release (ER) was effective and well tolerated for managing chronic diabetic peripheral neuropathy.
PAINWeek 2012
Hydrocodone Bitartrate ER Shown to be Effective for Chronic Pain
Hydrocodone Bitartrate ER may provide a new opioid option for subjects with chronic pain that is not alleviated by their current treatment, according to a study presented at PAINWeek 2012.
Once-Daily Gastroretentive Gabapentin Formulation Effective for Very Elderly with Postherpetic Neuralgia
A once-daily gastroretentive formulation of gabapentin, which for patients in the fed state lingers in the stomach for an estimated 8 hours, can be an efficacious option for postherpetic neuralgia, including a very elderly (age ≥75 years) population, as presented at PAINWeek 2012.
Satisfactory Symptom Relief from Fentanyl Sublingual Spray for Breakthrough Cancer Pain
Larry Dillaha, MD, of INSYS Therapeutics, Phoenix, AZ, and colleagues reported at PAINWeek 2012 that fentanyl sublingual spray markedly improved satisfaction with symptom relief among patients with breakthrough cancer pain (BTCP).
Hydromorphone ER Showed Similar Efficacy in Neuropathic and Non-Neuropathic Pain
Hydromorphone extended-release (ER) demonstrated similar efficacy in treating neuropathic or non-neuropathic chronic low back pain (LBP), as presented at PAINWeek 2012.
Lumbar Sympathetic Block Effective Over a Month with Botulinum Toxin Type B
At PAINWeek 2012, Francis Nahm, MD, of Seoul National University, Seoul, South Korea, and colleagues presented two cases studies where lumbar sympathetic block with botulinum toxin type B provided prolonged sympathetic pain blocking in patients with complex regional pain syndrome.
No Increased Cardiac Safety Risk with SC Methylnaltrexone for Chronic Pain
The cardiac safety of subcutaneous (SC) methylnaltrexone bromide is similar to placebo in patients with opioid-induced constipation and noncancer pain, reported Richard Rauck, MD, FIPP, of Carolinas Pain Institute, Winston-Salem, NC, at PAINWeek 2012.
KP511: A Novel Opioid Pain Therapy with Reduced Abuse Potential and Improved Safety
Opioids play an important role in the treatment of moderate-to-severe pain, but with an increasing market for pain therapies, diversion and abuse have escalated as well, reported Travis Mickle, PhD, of KemPharm, North Liberty, IA , at PAINWeek 2012.
Tapentadol IR Has Reduced GI Adverse Effects vs. Oxycodone IR in Acute Low Back Pain
A study comparing tapentadol immediate-release and oxycodone immediate-release in moderate-to-severe, acute low back pain with radicular leg pain demonstrated comparable efficacy, with reduced gastrointestinal side effects seen with the tapentadol immediate-release arm, investigators reported during PAINWeek 2012.
Polyethylene Oxide Tapentadol ER Formulation Proves Crush-Resistant
At PAINWeek 2012, study data showed that tapentadol extended-release (ER) tablets formulated with a polyethylene oxide matrix produced tablets that were resistant to crushing or extraction, as reported by Joseph Pergolizzi, MD, of Naples Anesthesia and Pain Associates, Naples, FL.
Want to read more?
Please login or register first to view this content.
